FLT1 Specific Neutra™ Antibody Products

Product list

FLT1, also known as VEGFR1, serves as a decoy receptor for vascular endothelial growth factor (VEGF), whose activation and subsequent downstream cascades may lead to various biological outcomes, contributing to pathological processes including but not limited to cancer and pulmonary fibrosis.

Structural of FLT1

FLT1 can bind with VEGF and placental growth factor, exhibiting widespread expression in vascular endothelial cells and peripheral blood monocytes. It belongs to the family of vascular endothelial growth factor receptors (VEGFRs), characterized structurally by extracellular ligand-binding domain, transmembrane domain, juxta membrane domain, split intracellular TK domain, and C-terminal tail.

Fig.1 VEGFR1/2 and ligands. (Uemura, et al., 2021) Fig.1 VEGFR1/2 and ligands.¹

Functional Attributes of FLT1

The primary function of FLT1 lies in modulating vascular development, influencing vascular permeability, and participating in homeostasis under physiological or pathological conditions through induction of VEGF activity upon binding with its ligand VEGF-A. Relative to another VEGF receptor, VEGFR2, FLT1 is widely acknowledged to possess minimal signaling activity and is regarded as a decoy receptor activating VEGF activity. Conversely, FLT1's other ligands, VEGF-B and PlGF, competitively bind with FLT1, thereby releasing VEGF-A and facilitating downstream pathway activation of VEGFR2.

FLT-Associated Diseases

In diseases related to tumors and angiogenesis, FLT1 and its ligand VEGF emerge as crucial associated targets. Compelling evidence also demonstrates that PlGF and VEGFR1 signaling not only impact tumor growth and metastasis but also influence the development of cardiovascular diseases and rheumatoid arthritis. Recent studies have further revealed that FLT1 undergoes differential regulation under hypoxia and inflammatory conditions, thereby affecting the growth and function of cells such as retinal and choroidal endothelial cells. Moreover, FLT1 plays a deleterious role in pulmonary fibrosis.

Fig.3 Mechanisms of IgE targeting CD23. (Engeroff, et al., 2021) Fig.2 VEGFR1 in retina and signaling pathway.¹

Our Services

As a cutting-edge biotechnology company, our neutralizing antibody and recombinant antibody services platform offers comprehensive solutions tailored to FLT1. Our technological advantages encompass custom antibody design and thorough antibody products tailored to specific customer needs, precise detection of FLT1 expression, and comprehensive support for targeted drug research and development. Our services are not only efficient and convenient but also reasonably priced, making us the ideal choice for your experimental exploration. We sincerely look forward to collaborating with you to advance medical research and clinical treatment continuously. Please don't hesitate to reach out to us for more information.